March 27, 2025 07:09 AM EDTUpdated 10:16 AM
R&D

Can­del to fo­cus on non-squa­mous lung can­cer fol­low­ing new sur­vival da­ta

Ayisha Sharma

News Reporter

Can­del Ther­a­peu­tics said Wednes­day that new da­ta on its vi­ral im­munother­a­py showed on­ly a mar­gin­al im­prove­ment in sur­vival of pro­gres­sive lung can­cer pa­tients com­pared with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

FDA's Pe­ter Marks re­signs, say­ing he won't ac­cept Kennedy's 'mis­in­for­ma­tion and lies'

Blue­bird gets new M&A bid, seek­ing to top pri­vate eq­ui­ty of­fer

BioN­Tech de­tails promis­ing mid-stage da­ta for its PD-L1xVEGF in ag­gres­sive lung can­cer

No­vo inks sec­ond obe­si­ty deal of the week, with Lex­i­con oral drug part­ner­ship worth up to $1B

‘Peo­ple will die’: End of NIH grants guts work be­tween aca­d­e­mics and com­pa­nies to counter next pan­dem­ic

Eu­ro­pean reg­u­la­tor re­jects Lil­ly's Alzheimer’s drug over po­ten­tial­ly fa­tal side ef­fects

A service from the Financial Times